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Abstract
Background: To examine the effects of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on visceral fat
adiposity, appetite, food preference, and biomarkers of cardiovascular system in Japanese patients with type 2
diabetes.
Methods: T h es t u d ys u b j e c t sw e r e2 0i n p a t i e n t sw i t ht y p e2d i a b e tes treated with liraglutide [age; 61.2 ± 14.0 years,
duration of diabetes; 16.9 ± 6.6 years, glycated hemoglobin (HbA1c); 9.1 ± 1.2%, body mass index (BMI); 28.3 ± 5.2 kg/m
2,
mean ± SD]. After improvement in glycemic control by insulin or oral glucose-lowering agents, patients were switched
to liraglutide. We assessed the estimated visceral fat area (eVFA) by abdominal bioelectrical impedance analysis, glycemic
control by the 75-g oral glucose tolerance test (OGTT) and eating behavior by the Japan Society for the Study of Obesity
questionnaire.
Results: Treatment with liraglutide (dose range: 0.3 to 0.9 mg/day) for 20.0 ± 6.4 days significantly reduced waist
circumference, waist/hip ratio, eVFA. It also significantly improved the scores of eating behavior, food preference
and the urge for fat intake and tended to reduce scores for sense of hunger. Liraglutide increased serum C-peptide
immunoreactivity and disposition index.
Conclusions: Short-term treatment with liraglutide improved visceral fat adiposity, appetite, food preference and
the urge for fat intake in obese Japanese patients with type 2 diabetes.
Keywords: liraglutide, glucagon-like peptide-1, obesity, eating behavior
Introduction
T h ep r e v a l e n c eo ft y p e2d i a b etes has rapidly increased
worldwide [1] including Western and Asian countries
[2]. Type 2 diabetes is a major risk for cardiovascular
events. Obesity, especially visceral fat adiposity, also
increases the risk of type 2 diabetes, hypertension, dysli-
pidemia, and atherosclerosis, suggesting that obese
patients with type 2 diabetes are at high risk for cardio-
vascular diseases [3]. The World Health Organization
(WHO) projects that 2.3 billion adults are overweight
and > 700 million are obese [4]. The association between
type 2 diabetes and overweight/obesity is indisputable. In
this sense, it is necessary to develop effective and efficient
therapeutic strategy for obese type 2 diabetes. However,
the treatment for obese type 2 diabetes often encounters
difficulties with regard to the control of weight and appe-
tite. Moreover, treatment with insulin, sulfonylurea, and
thiazolidinedione increase appetite and body weight,
frequently resulting in poor glycemic control.
Dietary fat intake alters glucose and lipid metabolism [5]
and correlates with cardiovascular risk in type 2 diabetes
[6]. The intake of animal fat, especially saturated fat, is
considered to be associated with type 2 diabetes and cardi-
ovascular diseases [7]. Higher intake of polyunsaturated fat
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dence of type 2 diabetes [8,9]. In addition to calorie
restriction, the control of food preference is also another
important factor in the treatment of obese type 2 diabetes.
Liraglutide is a glucagon-like peptide-1 (GLP-1) analo-
gue with 97% structural homology to human GLP-1.
Native GLP-1 has a short elimination half-life of 1-2 min,
whereas liraglutide has a long half-life of about 13 hours
and can be administered once a day [10]. GLP-1 is a
naturally occurring incretin hormone with a potent
blood-glucose lowering action only during hyperglycemia
because it induces insulin secretion and reduces glucagon
secretion in a glucose-dependent manner [11]. In addi-
tion, GLP-1 delays gastric emptying and induces satiety,
leading to decreased energy intake and weight reduction.
The underlying mechanisms of weight loss are most
probably a combination of the effects of GLP-1 on the
gastrointestinal tract and the brain [12]. Recent experi-
ments show that the anorectic effect of peripheral GLP-1
administration is mediated both by the activation of
G L P - 1r e c e p t o r( G L P - 1 R )e x p r e s s e do nv a g a la f f e r e n t s
and by the GLP-1R activation in central nervous system
[13]. GLP-1 also has various extrapancreatic actions such
as the cardiovascular system [4] and is considered a pro-
mising new agent for the treatment of type 2 diabetes
and cardiovascular diseases linked to obesity-type 2
diabetes.
In the present study, we investigated the effects of lir-
aglutide on visceral fat adiposity, eating behavior, and
cardiovascular biomarkers in controlled hospitalized
patients with type 2 diabetes.
Materials and methods
Subjects
All enrolled subjects were hospitalized in the Division of
Endocrinology & Metabolism, Osaka University Hospital.
They represented inpatients with type 2 diabetes treated
for the first time with liraglutide between August 2010
and April 2011. Upon admission, each patient was trea-
ted with insulin or oral glucose-lowering agents under
diet therapy to improve plasma glucose levels. After
achieving the target levels of glycemic control [fasting
plasma glucose (FPG) < 150 mg/dL and postprandial 2-h
plasma glucose < 200 mg/dL], treatment with insulin or
oral glucose-lowering agents was replaced with liraglutide
at 0.3 mg/day, which was increased by 0.3 mg/day every
one week to a final dose of 0.9 mg/day, representing the
maximum dose in Japan. Introduction of liraglutide was
decided by each attending physician after confirmation of
preserved b-cell function by the examination of fasting
serum C-peptide, daily urine C-peptide, and/or, glucagon
challenge test. Among the 20 study subjects, liraglutide
treatment failed to lower FPG to the target levels even at
0.9 mg/day in 8 patients (sulfonylurea (SU), n = 4;
biguanide (BG), n = 1; SU+BG, n = 3), necessitating the
addition of oral glucose-lowering agents according to the
assessment of the attending physician. Written consent
was obtained from each subject after explaining the pur-
pose and complications of the study. The study protocol
was approved by the human ethics committee of Osaka
University and was registered with the University hospital
Medical Information Network (Number: UMIN
000004192).
Clinical examination
Various metabolic parameters were measured on admis-
sion, liraglutide induction, and discharge. Waist circumfer-
ence at umbilical level was measured in standing position
with a non-stretchable tape in the late phase of expiration.
Estimated visceral fat area (eVFA) was measured by
abdominal bioelectrical impedance analysis (BIA), as
described previously [14].
Several diabetic parameters were examined before and
after liraglutide use. Each subject received a 75-g oral glu-
cose tolerance test (OGTT) after 10- to 12-h overnight
fast. Insulin secretion was evaluated by fasting serum C-
peptide (F-sCPR), C-peptide index (CPI), insulinogenic
index, and disposition index. Insulin resistance was
assessed by homeostasis model assessment of insulin resis-
tance (HOMA-IR) and the Matsuda index. These para-
meters were calculated by the following formula: CPI =
F-sCPR (ng/mL) × 100/fasting glucose (mg/dL), insulino-
genic index = [(insulin at 30 min) - (insulin at 0 min)]/
[ ( g l u c o s ea t3 0m i n )-( g l u c o s ea t0m i n ) ] ,H O M A - I R=
fasting glucose (mg/dL) × fasting insulin (μU/ml)/405,
composite (Matsuda) index and disposition index were cal-
culated using the MINMOD Millenium software [15,16].
High-sensitivity C-reactive protein (hsCRP) (N-Latex CRP
II, Dade Behring Inc, Marburg, Germany) and soluble
intercellular adhesion molecule-1 (sICAM-1) (Pierce Bio-
technology, Rockford, IL) were also measured before and
after liraglutide treatment.
To evaluate dietary intake, staple food and non-staple
food were quantified at each meal by the nurses. Every
intake of staple food and non-staple food was rated on an
eleven-point scale ranging from 0 (no intake) to 10 (full
intake), respectively. For example, if all staple food was
consumed every meal, the daily score for staple food
intake was 30 point/day. Scores were recalculated based
on previous prescribed total daily calorie when the diet
was changed. Food intake was quantified by the daily aver-
age intake from admission to liraglutide induction, and
from liraglutide induction to discharge, respectively.
Questionnaire for eating behavior
Eating behavior was assessed by using the questionnaire
of The Guideline For Obesity issued by the Japan Society
for the Study of Obesity (advocated by Prof. Hironobu
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treatment. This questionnaire consists of 55-item ques-
tions of seven major scales as follows: 1. Recognition for
weight and constitution (e.g., ‘Do you think it is easier for
you to gain weight than others?’, ‘Do you think you gain
weight because of less exercise?’), 2. External eating beha-
vior (e.g., ‘If food smells and looks good, do you eat more
than usual?’, ‘If you walk past the supermarket, do you
have the desire to buy something delicious?’, ‘If you see
others eating, do you also have the desire to eat?’), 3.
Emotional eating behavior (e.g., ‘Do you have the desire
to eat when you are irritated?’, ‘Do you have a desire to
eat when you have nothing to do?’), 4. Sense of hunger
(e.g. ‘Do you get irritated when you feel hungry?’, ‘Do you
often regret because you have eaten a lot of food?’), 5.
Eating style (e.g., ‘Do you eat fast?’, ‘Are you known to
eat a lot of food?’), 6. Food preference (e.g., ‘Do you often
eat snack bread?’, ‘Do you like meat?’, ‘Do you like noo-
dles?’), 7. Regularity of eating habits (e.g., ‘Is your dinner
time too late at night?’, ‘Do you gain body weight during
holidays?’). All items were rated on a four-point scale
ranging from 1 (seldom) to 4 (very often).
Statistical analysis
Results are expressed as mean ± standard deviation
(SD). All analyses were performed using JMP software
(JMP 8.0; SAS Institute Inc., Cary, NC). For comparison
of results obtained at admission, before and after liraglu-
tide treatment, the Student’s t-test was used.
Results
Characteristics of participants
Table 1 shows baseline characteristics of 20 subjects at
admission. The mean age was 61.2 years, body mass
index (BMI) 28.3 kg/m
2, and the duration of diabetes was
16.9 years. The mean glycated hemoglobin (HbA1c) was
9.1%. At baseline, 65% of patients were treated with insu-
lin (average dosage: 37.3 units/day, maximum dosage: 70
units/day). These parameters indicate that the enrolled
patients had relatively long duration of diabetes, mild
obesity, high frequency of insulin use, and high dosage of
insulin.
After admission, patients were started on insulin or
oral glucose-lowering agents under diet therapy until
glycemic control reached target levels, considered as
relief from gluco-toxicity, and were then introduced to
liraglutide treatment at 0.3 mg/day. The dose was gra-
dually increased according to blood glucose levels as
described in the Methods section. The number of
patients treated with liraglutide at 0.3, 0.6, and 0.9 mg/
day at discharge was 1, 9, and 10 patients, respectively.
The time period from admission to induction of liraglu-
tide was 11.1 ± 4.7 days and from induction to dis-
charge was 20.0 ± 6.4 days.
Changes in physical parameters and visceral fat adiposity
BMI was significantly reduced by 0.54 ± 0.11 kg/m
2 from
admission to liraglutide induction with further significant
decrease by 0.93 ± 0.12 kg/m
2 from liraglutide induction
to discharge (Figure 1A). The waist circumference
decreased by -0.30 ± 0.44 cm from admission to liraglutide
induction, and liraglutide treatment significantly decreased
waist circumferences by -4.28 ± 0.55 cm from liraglutide
induction to discharge (Figure 1B). The waist/hip (W/H)
ratio at admission, liraglutide induction, and discharge was
1.01 ± 0.07, 1.00 ± 0.06, and 0.97 ± 0.06, respectively, and
was significantly reduced by liraglutide (Figure 1C). The
eVFA at admission, liraglutide induction, and discharge
were 182.6 ± 68.3 cm
2, 178.1 ± 56.8 cm
2, and 153.4 ± 51.9
cm
2, respectively, (Figure 1D). Similar to waist circumfer-
ence and W/H ratio, liraglutide significantly reduced
eVFA compared with no significant change before liraglu-
tide induction.
Assessment of food intake, appetite, and food
preferences
Next, the effects of liraglutide on food intake, appetite,
and food preference were evaluated. Liraglutide signifi-
cantly decreased daily staple food intake (Figure 2A),
but did not change significantly the daily intake for
Table 1 Baseline characteristics
Sex (Male/Female) 8/12
Age (years) 61.2 ± 14.0
Duration of diabetes (years) 16.9 ± 6.6
HbA1c (%) 9.1 ± 1.2
Body mass index (kg/m
2) 28.3 ± 5.2
Waist circumference (cm) 100.0 ± 11.8
Waist-to-hip ratio 1.01 ± 0.07
Estimated visceral fat area (cm
2) 182.6 ± 68.3
LDL-C (mg/dL) 112.7 ± 29.1
HDL-C (mg/dL) 45.7 ± 8.8
Triglycerides (mg/dL) 141.6 ± 68.2
Uric acid (mg/dL) 6.0 ± 1.5
History of smoking (%) 30
Hypertension (%) 70
Dyslipidemia (%) 95
History of cardiovascular disease (%) 30
Medication for Diabetes
Biguanide (%) 50
Sulfonylurea (%) 45
Alpha-glucosidase inhibitor (%) 30
Thiazolidinedione (%) 25
DPP-IV inhibitor (%) 10
Glinide (%) 10
Insulin (%) 65
Data are mean ± SD or number of subjects. LDL-C; low-density lipoprotein-
cholesterol, HDL-C; high-density lipoprotein-cholesterol, DPP-IV; dipeptidyl
peptidase-IV.
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tionnaire on eating behavior at admission, pre- and
post-liraglutide as described in the Methods section. Fig-
ure 2C to 2E show changes in the scores for representa-
tive question headings; external eating behavior, sense of
hunger, and food preference. These score did not
change under conventional glucose-lowering treatment,
i.e., before liraglutide induction. However, treatment
with liraglutide significantly decreased the scores for
external eating behavior (Figure 2C) and tended to
decrease the sense of hunger (Figure 2D). The number
of patients who reported feeling full stomach was higher
after liraglutide induction. Interestingly, liraglutide
administration also decreased the score of food prefer-
ence, related to the obesity phenotype (Figure 2E), and
especially reduced the need for fat intake such as fatty
foods, meat diet, and snack breads (Figure 2F).
Effect of liraglutide treatment on glucose tolerance
OGTT was conducted just before liraglutide induction, i.
e., after relief of gluco-toxicity. Table 2 lists various
indices related to insulin sensitivity and insulin secretion
measured before and after induction of liraglutide
treatment. There were no significant differences in
HOMA-IR and the Matsuda index between pre- and
post-liraglutide, while fasting serum C-peptide immunor-
eactivity (F-sCPR) and C-peptide index (CPI) were signif-
icantly elevated by liraglutide treatment. Liraglutide also
increased the insulinogenic index and disposition index.
These data indicate that liraglutide ameliorates insulin
secretion as expected.
Effect of liraglutide treatment on biomarkers of
cardiovascular system
We also tested the effects of short-term liraglutide treat-
ment on biomarkers of cardiovascular system. Serum
hsCRP levels were significantly reduced by liraglutide
(1.10 ± 1.03 mg/L at liraglutide induction versus 0.70 ±
0.47 mg/L at discharge, P < 0.05). Treatment with lira-
glutide tended to decrease plasma concentrations of
sICAM-1 (198.23 ± 84.95 ng/mL at liraglutide induction
versus 180.99 ± 59.27 ng/mL at discharge, P = 0.067).
Discussion
The present study demonstrated that short-term liraglu-
tide treatment significantly affected visceral fat adiposity,
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in Japanese patients with type 2 diabetes.
The LEAD-2 trial showed that liraglutide at 1.2 and 1.8
mg/day significantly decreased waist circumference and
eVFA compared to the 4 mg/day glimepiride after 26
weeks from introduction, while there was no significant
difference in the reductions of waist circumference and
eVFA between liraglutide group and placebo group [17].
In the LEAD-3 substudy, a long-term liraglutide mono-
therapy significantly reduced body weight and fat mass
from baseline while body weight and fat mass were
increased in the glimepiride group [18]. In the present
study, waist circumference, W/H ratio, and eVFA did not
change while patients were treated with insulin and/or
oral glucose-lowering agents (Figure 1). However, treat-
ment with liraglutide significantly reduced these physical
parameters. Furthermore, the daily reduction of waist cir-
cumferences was significantly larger during liraglutide
treatment than before liraglutide introduction, suggesting
that liraglutide effectively decreased visceral fat adiposity.
Previous studies reported the lack of GLP-1 receptor
expression on adipocytes [19], but recent work has
demonstrated GLP-1 receptor expression on adipocytes
[20]. Although GLP-1 action and GLP-1 receptor signaling
in adipocytes have not been fully elucidated, the present
study demonstrated that liraglutide reduced visceral fat
adiposity in a direct or indirect fashion. The results also
point to a possible anti-atherosclerotic effect for liraglutide
partly through reduction of eVFA. Treatment with exena-
tide, another GLP-1 receptor agonist, exhibited a signifi-
cant weight reduction when used for 3 years [21]. Previous
study showed that body weight did not change following
the use of liraglutide by Japanese type 2 diabetes patients,
but the mean BMI of those patients was only 23.9 kg/m
2
[22]. As shown in Table 1 the mean BMI of our patients
was 28.3 kg/m
2, suggesting that the effect of liraglutide on
weight reduction is limited to obese type 2 diabetics.
Several studies have demonstrated that GLP-1 pro-
motes satiety and suppresses energy intake both in ani-
mals [23,24] and human subjects [25-28], however, the
effect of liraglutide on eating behavior has not been
examined in human type 2 diabetics. The present study
demonstrated that liraglutid er e d u c e df o o di n t a k ea n d
changed external eating behavior and food preference.
Liraglutide significantly reduced the intake for staple
food, e.g., rice and/or bread. Interestingly, liraglutide sig-
nificantly decreased the scores for external eating beha-
vior and food preference (Figure 2C and 2E). Questions
on external eating behavior evaluate appetite increase
through sight and smell senses. Questions about food
preference measure foods directly associated with obesity.
Such improvement in eating behavior induced by liraglu-
tide has not been reported foro t h e rg l u c o s e - l o w e r i n g
agents. Furthermore, liraglutide significantly reduced the
urge for fat intake (Figure 2F). Although the findings of
epidemiological studies on the association of total dietary
fat with type 2 diabetes have been inconsistent [29-32],
dietary fat intake impairs glucose metabolism [5] and is
strongly related to cardiovascular risk in type 2 diabetes
[6]. A high intake of saturated fat is considered to associ-
ate with type 2 diabetes and cardiovascular diseases [7].
In this sense, liraglutide may be beneficial in reducing fat
preference, related to obese type 2 diabetes, although the
long-term effects of liraglutide on eating behavior remain
to be elucidated. It would be better to refine the ques-
tions on food preference to identify the types of fat.
GLP-1 receptor agonist exerts glucose-lowering effect
mainly by stimulating glucose-mediated secretion of insu-
lin from b-cells. Insulin secretion is often deteriorated in
various degrees in Japanese and the other Asian patients
with type 2 diabetes compared to Caucasian [2], and thus
the effect of liragulutide on insulin secretion is worth eval-
uating in Japanese type 2 diabetes subjects. As shown
in Table 2 liraglutide treatment increased sCPR and C-
peptide Index, indicating that insulin secretion was
enhanced by liraglutide. Such changes may appear the
increases of HOMA-IR and Matsuda Index, suggesting
that these indices may not exactly reflect insulin sensitivity
under liraglutide treatment. There is a possibility that
long-term liraglutide treatment may ameliorate insulin
resistance by weight reduction through decrease of appe-
tite. Further clinical investigations may be needed in
future.
The extrapancreatic actions of GLP-1 have been
demonstrated, especially the beneficial its effect on the
cardiovascular system [4]. GLP-1 has a protective action
Table 2 Liraglutide-induced changes in parameters relating to glucose metabolism
Before treatment with liraglutide After treatment with liraglutide P value
sCPR(ng/mL) 1.87 ± 1.00 3.25 ± 1.19 < 0.0001
C-peptide Index 1.47 ± 0.75 2.76 ± 0.97 < 0.0001
HOMA-IR 3.52 ± 2.63 4.51 ± 3.27 0.468
Matsuda Index 3.09 ± 2.24 3.16 ± 1.99 0.820
Insulinogenic Index 0.18 ± 0.16 0.32 ± 0.30 0.058
Disposition Index 0.43 ± 0.27 0.76 ± 0.51 < 0.05
Data are mean ± SD. sCPR; serum C-peptide immunoreactivity, HOMA-IR; homeostasis model assessment of insulin resistance.
Inoue et al. Cardiovascular Diabetology 2011, 10:109
http://www.cardiab.com/content/10/1/109
Page 6 of 8on heart function and/or cardiomyocytes, although the
GLP-1 action on the vascular system has not been fully
evaluated especially in human. Treatment with GLP-1
improved endothelial dysfunction in type 2 diabetics
with ischemic heart diseases [33]. Interestingly, GLP-1
treatment improved postprandial hyperlipidemia, sug-
gesting the possibility that GLP-1 administration may
reduce cardiovascular disease risk in type 2 diabetes
[34]. A recent experiment showed that GLP-1 treatment
protected against the development of atherosclerosis
both in vivo and in vitro [35,36]. In the present study,
liraglutide decreased serum hsCRP and sICAM-1 levels,
while no such changes were observed following treat-
ment with other glucose-lowering agents with insulin
(n = 6), biguanide (BG) (n = 4), a-glucosidase inhibitor
(aGI) (n = 3), dipeptidyl peptidase-4 inhibitors (DPP-4i)
(n = 3), and sulfonylurea (SU) (n = 2) (data not shown).
These results suggest that the decrease in hsCRP and
sICAM-1 levels may be due to the pleiotropic effects of
liraglutide, beneficial for protection against the develop-
ment of atherosclerosis.
The present study has several limitations. The study is
not a randomized clinical trial (RCT) and is not a cross-
over study. A crossover clinical trial will confirm present
results. In addition, present study was performed in a
small population. The effects of liraglutide on visceral fat
adiposity, appetite, and cardiovascular biomarkers were
examined in a hospitalized term. Collectively, a long-term
RCT in obese Japanese type 2 diabetics should be con-
ducted to confirm the efficacy of liraglutide on visceral fat
adiposity, appetite, food behavior, and cardiovascular
events.
In summary, short-term treatment with liraglutide
effectively reduced visceral fat adiposity, appetite, and
cardiovascular biomarkers in obese Japanese patients
with type 2 diabetes. Longer term randomized clinical
trials are warranted to more thoroughly elucidate the
effect of liraglutide on these parameters.
Acknowledgements
We thank Miyuki Nakamura, Department of Metabolic
Medicine, Graduate School of Medicine, Osaka Univer-
sity, for the excellent technical assistance. This work was
supported in part by Grants-in-Aid for Scientific
Research (C) no. 22590979 (to N. M.) and Scientific
Research on Innovative Areas no. 22126008 (to T. F.).
This article is dedicated to the memory of Dr. Hironobu
Yoshimatsu, who was a professor of Oita University and
proposed the questionnaire of eating behavior.
Author details
1Department of Metabolic Medicine, Graduate School of Medicine, Osaka
University, 2-2-B5, Yamada-oka, Suita, Osaka 565-0871, Japan.
2Department of
Metabolism and Atherosclerosis, Graduate School of Medicine, Osaka
University, 2-2-B5, Yamada-oka, Suita, Osaka 565-0871, Japan.
Authors’ contributions
KI acquired and analyzed data, and wrote the manuscript. NM conceived
study, analyzed data, and wrote the manuscript. SK, YF, JK, AHS, KO, and AI
acquired and researched data. TF and IS reviewed manuscript. All authors
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 13 October 2011 Accepted: 1 December 2011
Published: 1 December 2011
References
1. Hossain P, Kawar B, El Nahas M: Obesity and diabetes in the developing
world-a growing challenge. N Engl J Med 2007, 356:213-215.
2. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB: Diabetes in
Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009,
301:2129-2140.
3. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I: Adiponectin and
metabolic syndrome. Arterioscler Thromb Vasc Biol 2004, 24:29-33.
4. Chilton R, Wyatt J, Nandish S, Oliveros R, Lujan M: Cardiovascular
comorbidities of type 2 diabetes mellitus: defining the potential of
glucagon-like peptide-1-based therapies. Am J Med 2011, 124:S35-S53.
5. Mensink RP, Zock PL, Kester AD, Katan MB: Effects of dietary fatty acids
and carbohydrates on the ratio of serum total to HDL cholesterol and
on serum lipids and apolipoproteins: a meta-analysis of 60 controlled
trials. Am J Clin Nutr 2003, 77:1146-55.
6. Tanasescu M, Cho E, Manson JE, Hu FB: Dietary fat and cholesterol and
the risk of cardiovascular disease among women with type 2 diabetes.
Am J Clin Nutr 2004, 79:999-1005.
7. Thanopoulou AC, Karamanos BG, Angelico FV, Assaad-Khalil SH, Barbato AF,
Del Ben MP, Djordjevic PB, Dimitrijevic-Sreckovic VS, Gallotti CA,
Katsilambros NL, Migdalis IN, Mrabet MM, Petkova MK, Roussi DP,
Tenconi MT: Dietary fat intake as risk factor for the development of
diabetes: multinational, multicenter study of the Mediterranean Group
for the Study of Diabetes (MGSD). Diabetes Care 2003, 26:302-7.
8. Meyer KA, Kushi LH, Jacobs DR Jr, Folsom AR: Dietary fat and incidence of
type 2 diabetes in older Iowa women. Diabetes Care 2001, 24:1528-35.
9. Devore EE, Stampfer MJ, Breteler MM, Rosner B, Hee Kang J, Okereke O,
Hu FB, Grodstein F: Dietary fat intake and cognitive decline in women
with type 2 diabetes. Diabetes Care 2009, 32:635-40.
10. Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M: The
pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211,
a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002,
45:195-202.
11. Holst JJ, Orskov C: The incretin approach for diabetes treatment:
modulation of islet hormone release by GLP-1 agonism. Diabetes 2004,
53:S197-S204.
12. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D:
Clinical review: The extrapancreatic effects of glucagon-like peptide-1
and related peptides. J Clin Endocrinol Metab 2009, 94:1843-1852.
13. Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR: Peripheral and central
GLP-1 receptor populations mediate the anorectic effects of peripherally
administered GLP-1 receptor agonists, liraglutide and exendin-4.
Endocrinology 2011, 152:3103-12.
14. Ryo M, Maeda K, Onda T, Katashima M, Okumiya A, Nishida M,
Yamaguchi T, Funahashi T, Matsuzawa Y, Nakamura T, Shimomura I: A new
simple method for the measurement of visceral fat accumulation by
bioelectrical impedance. Diabetes Care 2005, 28:451-453.
15. Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral
glucose tolerance testing: comparison with the euglycemic insulin
clamp. Diabetes Care 1999, 22:1462-1470.
16. Bergman RN, Ader M, Huecking K, Van Citters G: Accurate assessment of
beta-cell function: the hyperbolic correction. Diabetes 2002, 51:S212-S220.
17. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M,
Düring M, Matthews DR, Lead-2 Study Group: Efficacy and safety
comparison of liraglutide, glimepiride, and placebo, all in combination
Inoue et al. Cardiovascular Diabetology 2011, 10:109
http://www.cardiab.com/content/10/1/109
Page 7 of 8with metformin, in type 2 diabetes: the LEAD (liraglutide effect and
action in diabetes)-2 study. Diabetes Care 2009, 32:84-90.
18. Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, Düring M,
Zdravkovic M, Strauss BJ, Garber AJ, LEAD-2 and LEAD-3 Study Groups:
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1
analogue for type 2 diabetes treatment as monotherapy or added to
metformin, is primarily as a result of a reduction in fat tissue. Diabetes
Obes Metab 2009, 11:1163-72.
19. Hansotia T, Maida A, Flock G, Yamada Y, Tsukiyama K, Seino Y, Drucker DJ:
Extrapancreatic incretin receptors modulate glucose homeostasis, body
weight, and energy expenditure. J Clin Invest 2007, 117:143-152.
20. Kim Chung le T, Hosaka T, Yoshida M, Harada N, Sakaue H, Sakai T,
Nakaya Y: Exendin-4, a GLP-1 receptor agonist, directly induces
adiponectin expression through protein kinase A pathway and prevents
inflammatory adipokine expression. Biochem Biophys Res Commun 2009,
390:613-618.
21. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH,
Wintle ME, Maggs DG: Exenatide effects on diabetes, obesity,
cardiovascular risk factors and hepatic biomarkers in patients with type
2 diabetes treated for at least 3 years. Curr Med Res Opin 2008,
24:275-286.
22. Seino Y, Rasmussen MF, Zdravkovic M, Kaku K: Dose-dependent
improvement in glycemia with once-daily liraglutide without
hypoglycemia or weight gain: A double-blind, randomized, controlled
trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract
2008, 81:161-168.
23. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB:
Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body
weight and food intake in obese candy-fed rats, whereas a dipeptidyl
peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007, 56:8-15.
24. Raun K, von Voss P, Knudsen LB: Liraglutide, a once-daily human
glucagon-like peptide-1 analog, minimizes food intake in severely obese
minipigs. Obesity (Silver Spring) 2007, 15:1710-1716.
25. Flint A, Raben A, Astrup A, Holst JJ: Glucagon-like peptide 1 promotes
satiety and suppresses energy intake in humans. J Clin Invest 1998,
101:515-520.
26. Toft-Nielsen MB, Madsbad S, Holst JJ: Continuous subcutaneous infusion
of glucagon-like peptide 1 lowers plasma glucose and reduces appetite
in type 2 diabetic patients. Diabetes Care 1999, 22:1137-1143.
27. Gutzwiller JP, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J, Beglinger C:
Glucagon-like peptide-1 promotes satiety and reduces food intake in
patients with diabetes mellitus type 2. Am J Physiol 1999, 276:R1541-1544.
28. Verdich C, Flint A, Gutzwiller JP, Näslund E, Beglinger C, Hellström PM,
Long SJ, Morgan LM, Holst JJ, Astrup A: A meta-analysis of the effect of
glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in
humans. J Clin Endocrinol Metab 2001, 86:4382-4389.
29. Kawate R, Yamakido M, Nishimoto Y, Bennett PH, Hamman RF, Knowler WC:
Diabetes mellitus and its vascular complications in Japanese migrants
on the Island of Hawaii. Diabetes Care 1979, 2:161-70.
30. Marshall JA, Hamman RF, Baxter J: High-fat, low-carbohydrate diet and
the etiology of non-insulin-dependent diabetes mellitus: the San Luis
Valley Diabetes Study. Am J Epidemiol 1991, 134:590-603.
31. Tsunehara CH, Leonetti DL, Fujimoto WY: Diet of second-generation
Japanese-American men with and without non-insulin-dependent
diabetes. Am J Clin Nutr 1990, 52:731-8.
32. Tinker LF, Bonds DE, Margolis KL, Manson JE, Howard BV, Larson J, Perri MG,
Beresford SA, Robinson JG, Rodríguez B, Safford MM, Wenger NK,
Stevens VJ, Parker LM: Women’s Health Initiative. Low-fat dietary pattern
and risk of treated diabetes mellitus in postmenopausal women: the
Women’s Health Initiative randomized controlled dietary modification
trial. Arch Intern Med 2008, 168:1500-11.
33. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, Sjöholm A:
Effects of glucagon-like peptide-1 on endothelial function in type 2
diabetes patients with stable coronary artery disease. Am J Physiol
Endocrinol Metab 2004, 287:E1209-E1215.
34. Ansar S, Koska J, Reaven PD: Postprandial hyperlipidemia, endothelial
dysfunction and cardiovascular risk: focus on incretins. Cardiovasc
Diabetol 2011, 10:61.
35. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y,
Hirose T, Kawamori R, Watada H: Inhibition of monocyte adhesion to
endothelial cells and attenuation of atherosclerotic lesion by a
glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010,
59:1030-1037.
36. Gaspari T, Liu H, Welungoda I, Hu Y, Widdop RE, Knudsen LB, Simpson RW,
Dear AE: A GLP-1 receptor agonist liraglutide inhibits endothelial cell
dysfunction and vascular adhesion molecule expression in an ApoE
-/-
mouse model. Diab Vasc Dis Res 2011, 8:117-124.
doi:10.1186/1475-2840-10-109
Cite this article as: Inoue et al.: Short-term effects of liraglutide on
visceral fat adiposity, appetite, and food preference: a pilot study of
obese Japanese patients with type 2 diabetes. Cardiovascular Diabetology
2011 10:109.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Inoue et al. Cardiovascular Diabetology 2011, 10:109
http://www.cardiab.com/content/10/1/109
Page 8 of 8